Alexander Shaknovich, MD
Cardiovascular Disease · New York, NYNPI 1487741039
Payments from drug & device makers
Across 483 payments — averaging $45.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Boehringer Ingelheim$844
- Cvrx, Inc.$649
- Pfizer$531
- plus $5K from 33 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$9,50043%
- Travel & lodging$1,4597%
- Food & beverage$10,82249%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 53 | $12,471 |
| Novartis | 117 | $2,073 |
| E.r. Squibb & Sons, L.L.C. | 60 | $1,073 |
| Boehringer Ingelheim | 30 | $844 |
| Cvrx, Inc. | 5 | $649 |
| Pfizer | 27 | $531 |
| Amgen | 21 | $504 |
| Heartflow, Inc. | 23 | $473 |
| Amarin Pharma, Inc. | 19 | $423 |
| Edwards Lifesciences | 14 | $355 |
| Bardy Diagnostics, Inc. | 9 | $344 |
| GSK | 11 | $296 |
| Irhythm Technologies, Inc. | 11 | $210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $210 |
| Regeneron Healthcare Solutions, Inc. | 9 | $163 |
| AstraZeneca | 8 | $140 |
| Bolton Medical Inc | 1 | $130 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| Esperion Therapeutics, Inc. | 4 | $117 |
| Merck | 5 | $104 |
| Bayer | 5 | $99 |
| Medtronic | 3 | $97 |
| Lexicon Pharmaceuticals, Inc. | 4 | $96 |
| Boston Scientific | 3 | $87 |
| Lundbeck LLC | 5 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Insmed, Inc. | 2 | $50 |
| Scpharmaceuticals Inc. | 1 | $47 |
| Abbott | 2 | $42 |
| Biotronik Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Novo Nordisk | 2 | $37 |
| Gilead | 2 | $28 |
| Astellas Pharma US Inc | 2 | $27 |
| Validus Pharmaceuticals LLC | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$11,484
- Barostim Neo System$517
- Relay Plus$130
- ELIQUIS$123
How this compares
$22,183 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,196 | $827,263 |
| EntrestoSacubitril/Valsartan | 591 | $368,313 |
| MultaqDronedarone Hcl | 218 | $196,697 |
| XareltoRivaroxaban | 184 | $127,873 |
| Repatha SureclickEvolocumab | 191 | $110,702 |
| JardianceEmpagliflozin | 169 | $107,340 |
| VascepaIcosapent Ethyl | 270 | $104,691 |
| FarxigaDapagliflozin Propanediol | 134 | $92,989 |
| Praluent PenAlirocumab | 143 | $77,332 |
| VerquvoVericiguat | 53 | $34,895 |
| BrilintaTicagrelor | 26 | $21,268 |
| Metoprolol Succinate | 2,162 | $20,515 |
| LivaloPitavastatin Calcium | 47 | $18,391 |
| Ranolazine ErRanolazine | 301 | $16,236 |
| BystolicNebivolol Hcl | 64 | $12,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $531 | $827,2631,196 claims |
| NovartisEntresto, Diovan | $2,073 | $371,251604 claims |
| Sanofi-aventis U.S. LLCMultaq, Plavix | $69 | $205,141247 claims |
| Johnson & JohnsonXarelto | $12,471 | $127,873184 claims |
| AstraZenecaFarxiga, Brilinta | $140 | $114,257160 claims |
| Boehringer IngelheimJardiance | $844 | $107,340169 claims |
| MerckVerquvo | $104 | $34,89553 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $12 | $30,691111 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $37 | $4,24619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.